Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats

Eur J Pharmacol. 1992 Feb 25;212(1):9-13. doi: 10.1016/0014-2999(92)90065-c.

Abstract

The mechanism of the inhibitory action of rebamipide, a new mucosal protective drug, was studied using rats with diethyldithiocarbamate-induced gastric antral ulcers. Rebamipide reduced ulcer formation and inhibited the elevation in lipid peroxide concentration in the gastric mucosa. Rebamipide inhibited both luminol- and lucigenin-dependent chemiluminescence of neutrophils activated by formyl-methionyl-leucyl-phenylalanine. Rebamipide did not alter the reduction of cytochrome c induced by the xanthine-xanthine oxidase system or the NADPH-dependent microsomal lipid peroxidation in the liver. These findings suggest that rebamipide prevents diethyldithiocarbamate-induced gastric ulcer formation by inhibiting neutrophil activation.

MeSH terms

  • Alanine / analogs & derivatives*
  • Alanine / pharmacology
  • Alanine / therapeutic use
  • Animals
  • Anti-Ulcer Agents / pharmacology
  • Anti-Ulcer Agents / therapeutic use*
  • Cytochrome c Group / metabolism
  • Ditiocarb
  • Gastric Mucosa / drug effects*
  • Gastric Mucosa / metabolism
  • Lipid Peroxidation / drug effects*
  • Male
  • Microsomes, Liver / drug effects*
  • Microsomes, Liver / metabolism
  • Neutrophils / drug effects
  • Neutrophils / metabolism
  • Oxidation-Reduction
  • Quinolones / pharmacology
  • Quinolones / therapeutic use*
  • Rats
  • Rats, Inbred Strains
  • Stomach Ulcer / chemically induced
  • Stomach Ulcer / drug therapy*

Substances

  • Anti-Ulcer Agents
  • Cytochrome c Group
  • Quinolones
  • Ditiocarb
  • rebamipide
  • Alanine